Kura Oncology (KURA)
(Delayed Data from NSDQ)
$22.17 USD
-0.81 (-3.52%)
Updated May 17, 2024 04:00 PM ET
After-Market: $22.20 +0.03 (0.14%) 6:40 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Brokerage Reports
Kura Oncology, Inc. [KURA]
Reports for Purchase
Showing records 181 - 200 ( 254 total )
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; Strategic Focus for Optimized Resource Use Makes Sense to Us
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - The Wedbush Monthly Check-Up: May 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2019 Results; Continuing to Build a Strong Precision Targeted Thesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Tipifarnib HNSCC Study On Track with Fast Track
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Fast Track and Increasing Visibility on AIM-HN as We Near First End-Game
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Looks Like Tipifarnib Ready for Prime Time in AITL
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
AITL Update at ASH; FDA Gives Nod to Registration-Directed Ph 2 Design
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; AIM-HN Pushes Forward and ASH Bringing Important Heme Updates
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Update for Tipifarnib in AITL Patients Ahead at ASH
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Ph 2 HNSCC Update Points to High Likelihood of Success for AIM-HN Pivotal Study
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Compelling RUN-HN Update Strengthens Confidence in Pivotal AIM-HN Outcome
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D